Recent meta-analyses have concluded that the use of calcium-channel blockers can reduce the risk of developing Parkinson’s disease by up to 30% (Lang et al., 2015), and blockers of CaV1.3 for treating Parkinson’s by reducing mitochondrial impairment and neuroinflammation are currently in Phase III clinical trials (Swart and Hurley, 2016). The gene discussed is CACNA1D; the disease is Parkinsonism.